Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17558380 | 1.00 | ALDH1A1 (0.38) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL17542382 | 0.84 | ALDH1A1 (0.38) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL17542383 | 0.84 | ALDH1A1 (0.38) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL21930080 | 0.83 | SIGMAR1 (0.42) | ALDH1A1MEN1KMT2AMAPTKDM4C | |
| SCHEMBL21929993 | 0.83 | SIGMAR1 (0.42) | ALDH1A1MEN1KMT2AMAPTKDM4C | |
| SCHEMBL21930331 | 0.83 | SIGMAR1 (0.42) | ALDH1A1MEN1KMT2AMAPTKDM4C | |
| SCHEMBL26858688 | 0.81 | HRH3 (0.40) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL23442101 | 0.79 | KDM1A (0.41) | HPGDMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL17542336 | 0.78 | KDM4C (0.39) | HPGDMAPTSMN1; SMN2KDM4CSIGMAR1 | |
| SCHEMBL17542334 | 0.78 | KDM4C (0.39) | HPGDMAPTSMN1; SMN2KDM4CSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | AMGEN INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | AMGEN INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| EP-3762393-B1 | ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORE OR BIOISOSTERE MCL-1 PROTEIN ANTAGONISTS | AMGEN INC (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3601297-B1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2022-10-19 | — | — | EP | disclosed |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-11274105-B2 | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists | AMGEN INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190023720-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2019-01-24 | — | — | US | disclosed |
| US-20190016736-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2019-01-17 | — | — | US | disclosed |
| EP-3424931-A2 | TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN | Amgen, Inc (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-3186259-B1 | TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-10100063-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180289720-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2018-10-11 | — | — | US | disclosed |
| US-20170088560-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9562061-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | ALDH1A1 1891/4885HPGD 2525/4885MEN1 999/4885 |
| US-20180289720-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | ALDH1A1 1575/4885HPGD 2609/4885MEN1 761/4885 |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | ALDH1A1 1431/4885HPGD 2310/4885MEN1 659/4885 |
| US-20190023720-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | ALDH1A1 1891/4885HPGD 2525/4885MEN1 999/4885 |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | ALDH1A1 1891/4885HPGD 2525/4885MEN1 999/4885 |
| US-10100063-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | ALDH1A1 1891/4885HPGD 2525/4885MEN1 999/4885 |
| US-20190016736-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL2L1, BCL9 | ALDH1A1 1431/4885HPGD 2310/4885MEN1 659/4885 |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | ALDH1A1 1575/4885HPGD 2609/4885MEN1 761/4885 |
| US-20170088560-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | ALDH1A1 1891/4885HPGD 2525/4885MEN1 999/4885 |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | MCL1, BAK1, BCL2A1 | ALDH1A1 393/4885HPGD 2936/4885MEN1 76/4885 |
| US-11274105-B2 | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists | MCL1, BCL2A1, BCLAF1 | ALDH1A1 59/4885HPGD 798/4885MEN1 958/4885 |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | ALDH1A1 1891/4885HPGD 2525/4885MEN1 999/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | ALDH1A1 1891/4885HPGD 2525/4885MEN1 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.